Emyria announces focus on revenue-generation over low-dose CBD product registration, with phase III trial for psychological distress treatment on hold. Attention shifted to MDMA and psilocybin therapy, supported by Authorised Prescriber status for PTSD treatment. Long-term plans for synthetic CBD medicines remain, but current focus on MDMA therapy to drive short-term patient impact and revenue.
Read the full story here
Written by: Steve Jones
Published on February 7, 2024 at 01:34PM
Source: Cannabiz (opens in new tab)